Shelton Wealth Management LLC Takes $843,000 Position in Halozyme Therapeutics, Inc. $HALO

Key Points

• Shelton Wealth Management LLC purchased 16,196 shares of Halozyme Therapeutics, valued at approximately $843,000, as part of their second-quarter investment strategy.
• Insiders at Halozyme Therapeutics sold a total of 104,000 shares worth $6.77 million in the last 90 days, indicating significant trading activity among company executives.
• Analysts have mixed ratings on Halozyme, with price targets ranging from $55.00 to $91.00, and a consensus rating of "Hold" among market analysts.

Shelton Wealth Management LLC acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 16,196 shares of the biopharmaceutical company's stock, valued at approximately $843,000.

Several other hedge funds have also recently modified their holdings of the stock. Isthmus Partners LLC lifted its holdings in shares of Halozyme Therapeutics by 2.5% during the first quarter. Isthmus Partners LLC now owns 6,875 shares of the biopharmaceutical company's stock worth $439,000 after purchasing an additional 169 shares during the period. OneDigital Investment Advisors LLC lifted its holdings in shares of Halozyme Therapeutics by 1.7% during the first quarter. OneDigital Investment Advisors LLC now owns 10,176 shares of the biopharmaceutical company's stock worth $649,000 after purchasing an additional 175 shares during the period. Park Place Capital Corp lifted its holdings in shares of Halozyme Therapeutics by 20.1% during the first quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company's stock worth $69,000 after purchasing an additional 182 shares during the period. Xponance Inc. lifted its holdings in shares of Halozyme Therapeutics by 1.1% during the first quarter. Xponance Inc. now owns 18,652 shares of the biopharmaceutical company's stock worth $1,190,000 after purchasing an additional 198 shares during the period. Finally, Bessemer Group Inc. lifted its holdings in shares of Halozyme Therapeutics by 62.9% during the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock worth $34,000 after purchasing an additional 207 shares during the period. 97.79% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. The Goldman Sachs Group assumed coverage on Halozyme Therapeutics in a report on Thursday, July 10th. They issued a "neutral" rating and a $55.00 target price for the company. Wall Street Zen downgraded Halozyme Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, September 5th. JMP Securities raised their target price on Halozyme Therapeutics from $78.00 to $91.00 and gave the company a "market outperform" rating in a report on Wednesday, August 6th. Morgan Stanley raised their target price on Halozyme Therapeutics from $75.00 to $80.00 and gave the company an "overweight" rating in a report on Monday, August 18th. Finally, Zacks Research raised Halozyme Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, September 2nd. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $68.22.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction dated Wednesday, September 3rd. The stock was sold at an average price of $74.44, for a total value of $1,488,800.00. Following the completion of the sale, the chief executive officer owned 733,719 shares in the company, valued at $54,618,042.36. The trade was a 2.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Bernadette Connaughton sold 4,000 shares of Halozyme Therapeutics stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $73.68, for a total value of $294,720.00. Following the completion of the sale, the director owned 46,952 shares of the company's stock, valued at $3,459,423.36. This trade represents a 7.85% decrease in their position. The disclosure for this sale can be found here. Insiders sold 84,000 shares of company stock worth $5,696,520 in the last 90 days. 2.90% of the stock is owned by company insiders.

Halozyme Therapeutics Price Performance

Halozyme Therapeutics stock traded down $0.67 during midday trading on Tuesday, reaching $77.61. 902,544 shares of the company were exchanged, compared to its average volume of 1,965,839. The company has a market capitalization of $9.08 billion, a price-to-earnings ratio of 17.81, a P/E/G ratio of 0.43 and a beta of 1.19. The firm's 50-day simple moving average is $67.54 and its 200-day simple moving average is $61.22. Halozyme Therapeutics, Inc. has a 1 year low of $42.01 and a 1 year high of $79.50. The company has a debt-to-equity ratio of 4.54, a quick ratio of 7.01 and a current ratio of 8.36.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $1.54 EPS for the quarter, topping analysts' consensus estimates of $1.23 by $0.31. The firm had revenue of $325.72 million during the quarter, compared to analysts' expectations of $282.66 million. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The firm's quarterly revenue was up 40.8% compared to the same quarter last year. During the same quarter last year, the business posted $0.91 EPS. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. On average, analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.